With millions of Americans now using semaglutide, tirzepatide, and related therapies, RDNs are encountering new patterns of appetite suppression, food aversions, reduced portion tolerance, digestive sensitivities, and changing attitudes toward alcohol, indulgence, and social eating
The reasoning offered is that a medication improving insulin sensitivity might address some metabolic drivers, though that remains a hypothesis rather than a finding
As noted previously, currently we do not have any large clinical trials for the treatment of HF or CKD in patients with or without T2D using GLP-1RA
Conclusion Both Pantoprazole and Lansoprazole have a long history of usage in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and other conditions associated with excess stomach acid
Calculate volume: Target concentration matters, e.g., for a 5 mg vial, 2 mL bacteriostatic water yields 2.5 mg/mL (easy dosing math)